TMP/SMX

(redirected from TMPSMX)

TMP/SMX

Abbreviation for trimethoprim-sulfamethoxazole.
References in periodicals archive ?
Agents typically used are trimethoprim, TMPSMX, or nitrofurantoin (31,32) (table 4 (31)), none of which demonstrated superiority in a Cochrane review.
A prior study showed that clindamycin and TMPSMX are both of benefit in the setting of large skin abscesses.
bethesdensis CRO/GEN/VAN, Recovered CRO/DOX/TMPSMX, CFD/DOX/TMPSMX, DOX/TMPSMX * AMK, amikacin; CAZ, ceftazidime; CFD, cefdinir; CGD, chronic granulomatous disease; CLI, clindamycin; CLR, clarithromycin; CIP, ciprofloxacin; CPD, cefpodoxime; CRO, ceftriaxone; CSP, caspofungin; CYBB, cytochrome b-245, [beta] polypeptide; DOX, doxycycline; GEN, gentamicin; HSCT, hematopoietic stem cell transplant; IFN-[gamma], interferon-[gamma]; INH, isoniazid; ITZ, itraconazole; LAMB, liposomal amphotericin B; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MTZ, metronidazole; NCF2, neutrophil cytosolic factor 2; RFB, rifabutin; RIF, rifampin; TEC, teicoplanin; TGC, tigecycline; TMPSMX, trimethoprim/sulfamethoxazole; TOB, tobramycin; VAN, vancomycin; VRZ, voriconazole.
maltophilia and is the agent of choice in individuals intolerant of TMPSMX, or if the organism is resistant to TMPSMX.
La creciente evidencia sobre la relacion del TMPSMX con el riesgo de hiperhalemia y muerte subita debe ser complementada con estudios que permitan determinar aspectos como el efecto dosis/respuesta del antimicrobiano en distintas infecciones y las posibles interacciones con otros medicamentos diferentes de ios estudiados.
TMPSMX, used in combination with rifampin, promptly resolved 6 out of 6 CA-MRSA isolate SSTIs (Iyer & Jones, 2004).
The use of the recommended alternative, TMPSMX, has remained low and stable.
7% for TMPSMX, and in the evaluable population the rates were 89.
Acquired resistance to doxycycline is 2% and to TMPSMX is geographically variable (2.
5% of cases in Thailand; 14), and the chance of neurologic disease with a strain that is resistant to TMPSMX developing in a patient is low.
medical institutions that submit such information to an electronic database, 39% were resistant to ampicillin, 18% were resistant to TMPSMX, and 2% were resistant to ciprofloxacin, reported Dr.
Whether these mutations confer resistance to TMPSMX or dapsone plus trimethoprim for PCP treatment remains unclear.